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Tiffany A. Katz*
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A first full-term birth at an early age protects women against breast cancer by reducing 
lifetime risk by up to 50%. The underlying mechanism resulting in this protective effect 
remains unclear, but many avenues have been investigated, including lobular differen-
tiation, cell fate, and stromal composition. A single pregnancy at an early age protects 
women for 30–40 years, and this long-term protection is likely regulated by a relatively 
stable yet still modifiable method, such as epigenetic reprograming. Long-lasting epigen-
etic modifications have been shown to be induced by pregnancy and to target the IGF 
pathway. Understanding how an early first full-term pregnancy protects against breast 
cancer and the role of epigenetic reprograming of the IGF system may aid in developing 
new preventative strategies for young healthy women in the future.
Keywords: insulin-like growth factor i, pregnancy, mammary gland biology, breast cancer risk, breast cancer 
prevention
iNTRODUCTiON
An early first full-term birth (FFTB) is the most effective modifiable breast cancer prevention 
method, with the potential of reducing a woman’s lifetime risk up to 50%. The first documented 
observation of this preventative behavior was by Bernardino Ramazzini in 1700. He noted that 
“tumors of the breast are found more often in nuns than any other women” and speculated that 
this was due to a life of celibacy (1). A landmark case–control study revisited this phenomenon 
in 1970, finding that compared to nulliparous women, women who underwent their FFTB before 
the age of 20 had a risk reduction of 50%. In this study of 17,022 women (4323 cases and 12,699 
controls) in 7 regions around the world, a strong positive linear relationship between age at FFTB 
and breast cancer risk was observed (2). Since then, others have reproduced these findings showing 
that women who experience their FFTB before the age of 20 or 25 reduce their lifetime risk by 50 
or 38%, respectively (3–5). An increased number of births is also associated with decreased breast 
cancer risk, and these associations are stronger for estrogen receptor (ER)+ disease (6–10).
The abovementioned study identified a positive linear correlation between age at FFTB and breast 
cancer risk (2). Nulliparous women were used as the reference group. Women who give birth for the 
first time above the age of 33 were no longer protected against breast cancer compared to nulliparous 
women. In fact, those women were now at an increased risk compared to nulliparous women. This 
is especially concerning since the average age at FFTB in the United States has been increasing over 
time (11). The proportion of women who gave birth for the first time between the ages of 30 and 34 
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rose 28% (from 16.5 to 21.1%) and those over 35 years of age rose 
23% (from 7.4 to 9.1%) between 2000 and 2014 (11). Learning 
more about the mechanism underlying the protective effect of an 
early FFTB against breast cancer could help to provide protection 
for women giving birth at an older age.
The protective effect of pregnancy has been replicated in 
multiple animal models including mice and rats using both 
carcinogen and spontaneous carcinoma models (4, 12, 13). 
Simply replicating the hormonal milieu of pregnancy has been 
shown to induce robust protection against mammary tumors 
(14–16). Given at a dose resulting in circulating levels similar to 
pregnancy, estradiol (E2) alone decreases the percent of tumor 
bearing animals in response to a carcinogen; and E2 in combi-
nation with progesterone (P4) enhances this protective effect 
presumably by creating an environment even more similar to a 
pregnant state (14, 15). Additionally, the parous mammary gland 
is less successful in supporting the development of hyperplastic 
lesions or tumors. In a syngeneic rat model, carcinogen-treated 
epithelial cells were transplanted into uniparous, age-matched 
virgin (AMV), or young virgin (YV) rats. Compared to either 
group of virgin rats, transplants into uniparous rats had fewer 
hyperplasias and adenocarcinomas (17).
The stage of the pregnancy cycle (i.e., pregnancy, lactation, 
or involution) most important in reducing breast cancer risk is 
unclear. The previously mentioned study (2) chose to include 
regions across the globe in order to capture women who 
breastfed for extended periods of time and women who rarely 
breast fed but was unable to confirm a link between breast 
feeding and breast cancer risk. Other studies have reported 
associations between breast feeding and breast cancer risk. In 
a meta-analysis of 31 studies, 27 included breast feeding data 
and 13 of those found that longer durations of breast feeding 
protected against breast cancer (18). The current recommenda-
tion by physicians is that breast feeding for longer than 2 years 
over a woman’s lifetime is protective against breast cancer, and 
this is supported by multiple studies. Breast feeding for as little 
as 6  months (19) provides a significant reduction in breast 
cancer risk, but longer durations of breast feeding are even 
more beneficial (20–23).
Surprisingly, in a rodent model, lactation is not obligatory to 
elicit protection against mammary cancer. Parous rats that were 
not permitted to nurse and animals that did nurse were equally 
protected from mammary cancer (24). Additionally, the lacto-
genic drug perphenazine was not sufficient in protecting against 
mammary cancer (14).
POTeNTiAL MeCHANiSMS: LOBULAR 
DiFFeReNTiATiON, CeLL FATe, AND 
STROMAL COMPOSiTiON
Lobular Differentiation
In an attempt to identify the underlying cause of parity-induced 
protection against breast cancer, several morphogenic and molec-
ular mechanisms have been investigated including differentiation 
state, cell fate, and stromal alterations of the mammary gland. One 
of the first comprehensive studies investigating differentiation of 
the breast reported that parous women displayed a higher pro-
portion of differentiated lobules in the breast. Four lobule types 
were identified with type 1 being the least and type 4 being the 
most differentiated. Cells isolated from the least differentiated 
lobule type were the most susceptible to carcinogenic insults, 
displaying increased survival efficiency and multinucleation (25). 
Of peak importance, parous women who developed breast cancer 
displayed lobular profiles identical to nulliparous women. This 
indicates that these women may not have undergone the entire 
differentiation cycle required for the protective effect of parity 
against breast cancer (26–28).
Interestingly, in a more recent report, proportions of differ-
entiated and undifferentiated lobules were not different between 
parous and nulliparous women (29). The two studies used distinct 
lobule identification techniques and sampling methods. The 2014 
study used previously established imaging and quantitation crite-
ria, described by Russo (26), and Milanese et al. (30), to determine 
the proportion of lobule types represented in each specimen. 
When comparing samples from nulliparous women and women 
>10 years postpartum (n = 10), there was no difference in lobular 
composition of the breast (29). The more recent study included 
women who underwent clinically indicated breast biopsies 
including only one specimen per sample, whereas the previ-
ously mentioned studies included whole breast or lumpectomy 
samples, which were divided several times providing numerous 
samplings per patient. These differences may have contributed to 
the discrepancy between studies.
It has been hypothesized that type 1 lobules in parous 
women may all appear histologically the same, but some may 
have regressed from a type 3 or 4 lobule and may actually be 
functionally and molecularly different from immature type 1 
lobules in nulliparous women. This lobular regression has been 
termed age-related lobular involution. Studies investigating 
age-related lobular involution have found that women with 
predominately type 1 lobules and no type 3 lobules (i.e., lobular 
proportions similar to nulliparous women in the first study), 
have likely undergone lobular involution, and actually have a 
decreased risk for breast cancer (30, 31). These epidemiological 
data support the study by Jindal et al.; their finding may indicate 
that in women >10 years postpartum age-related involution may 
have occurred.
Cell Fate
While controversial, it is believed that changes in cell fate may 
contribute to the protective effect of pregnancy (32). Pregnancy 
modulates mammary stem cell number and function, but the 
long-term implications of these changes are unclear (33). Basal 
stem cells and alveolar progenitor cells populate the gland in 
preparation for lactation (34, 35). Shifts in these populations of 
cells could contribute to the protective effect of parity against 
breast cancer (36), but this is not a consistent finding (12, 37). 
Pathways involved in cell fate (wnt/notch) have been shown to 
be significantly altered with parity in both rodent models and 
women. In a murine gene expression array study, wnt2 was down-
regulated in the mouse involuted mammary gland compared 
to nulliparous controls (38). Additionally, the ligand wnt4 and 
the number of wnt4-secreting cells were dramatically reduced 
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in parous mammary glands compared to nulliparous  (39, 40). 
Of additional importance, wnt4 is lower in breast tissue from 
parous women who also display a reduction in CD44+p27+ cells 
(41). p27 is known to affect the number and proliferation of stem 
cells and may therefore indicate a reduction in the number of 
mammary progenitor cells in parous breast tissue.
Stromal Composition
Dramatic alterations in the parous stromal microenvironment 
have been well documented. The tissue microenvironment is 
extremely plastic in the breast especially during pregnancy. At this 
time, there is a great proliferative effort in the epithelial compart-
ment, while the adipose cells are reduced and acini are formed. 
Acini begin producing and releasing milk, and the breast becomes 
engorged for lactation. During involution, the gland undergoes a 
dramatic reconstruction very similar to wound healing. During 
these stages, the gland becomes filled with activated fibroblasts 
and immune infiltration (42). These changes contribute to an 
enriched extracellular matrix (ECM), which becomes stiffer and 
more collagen dense with an increased stroma/parenchyma ratio 
(38, 43–46). Gene expression studies in rodents and humans 
have supported these findings showing that ECM and immune 
gene signatures can differentiate between parous and nulliparous 
breast tissue (47–49).
Of greater interest is the role these stromal alterations play 
in preventing tumorigenesis. In a syngeneic rat model, the post-
partum epithelial structure was required for pseudopregnancy 
to protect the gland from breast cancer (50). In this study, 
epithelial cells were isolated from mice treated with a carcinogen 
and transplanted into parous animals, which either had their 
fat pad cleared prior to puberty or retained complete epithelial 
structures. Transplants into animals with a cleared fat pad 
displayed increased hyperplasia and carcinoma growth, while 
animals with full epithelial structure, which had been exposed to 
a pregnancy, were protected from carcinogenesis (50). In a simi-
lar study, mammary epithelial cells isolated from animals that 
were treated with a carcinogen were implanted into YVs, AMVs, 
and uniparous animals with cleared fat pads. Significantly fewer 
transplants grew in uniparous animals (14%), compared to 33% 
in AMV and 55% in YV, and significantly fewer hyperplasias 
developed in the transplants in uniparous animals (17). These 
data indicate that both the presence of epithelial cells and the 
stromal status are important in determining outgrowth of 
tumorigenic cells.
The ECM composition has been shown to effect breast cancer 
cell growth (51–56). Particularly, the stiffness of the matrix can 
influence which signaling cascades become activated, as well as 
migration and cellular organization phenotypes. In response to 
prolactin, T47D cells in a high density/stiff matrix migrate less 
and signal through the FAK/ERK pathway, while in low density/
compliant matrix, they will migrate more but signal through the 
canonical JAK/STAT pathway (52). In a follow-up report, the 
interaction between E2 and prolactin was highly influenced by 
matrix stiffness (51). Since stromal composition and density are 
dramatically effected by parity, it is likely that these factors work 
together to influence the protective effect of parity against breast 
cancer.
A ROLe FOR iNSULiN-LiKe GROwTH 
FACTOR i iN THe PROTeCTive eFFeCT 
OF PReGNANCY: ePiDeMiOLOGiCAL 
DATA AND RODeNT MODeLS
epidemiological Data
Insulin-like growth factor I (IGFI) in circulation has been shown 
in many studies to be associated with breast cancer risk (57–59). 
In a nested case–control study using the Nurses Health Study data, 
in premenopausal women, higher circulating IGFI was associated 
with a significant increase in breast cancer risk (60). Increased 
breast cancer risk was also associated with higher circulating IGFI 
measured during the first pregnancy (61). The Northern Sweden 
Maternity Cohort used a nested case–control design including 
244 cases and 453 controls. In this study, circulating IGFI was 
higher in cases than controls and breast cancer risk increased 
significantly with higher IGFI tertiles. Compared to the lowest 
tertile, women in the highest IGFI tertile had a 73% increase in 
breast cancer risk (61). However, this was not replicated in two 
other studies: one using the AVON Longitudinal Study of Parents 
and Children Cohort (62) and another in the Finnish Maternity 
Cohort (63). Therefore, chronic exposure to high circulating IGFI 
may have a bigger impact than exposure to elevated levels during 
pregnancy.
While it is well accepted that circulating IGFI levels are asso-
ciated with breast cancer risk, interestingly, parity is associated 
with lower circulating IGFI levels. In the Nurses Health Study, 
1037 healthy women were used to investigate circulating IGFI 
and lifestyle factors. This study identified age, smoking, parity, 
and hormone use to be significantly associated with circulat-
ing IGFI levels (64). Circulating IGFI was significantly lower 
in parous women and was inversely correlated with number of 
births, which parallels the data on breast cancer risk and parity 
(64). These observations support the hypothesis that reduced 
IGFI postpartum contributes to the protective effect of pregnancy 
against breast cancer.
The Nurses Health Study data also show an inverse relationship 
between IGFI levels and age (64). This finding is indicative of the 
gradual decline of the growth hormone (GH)/IGF axis with age 
eventually leading to somatopause (65, 66). This is particularly 
interesting since the highest level of protection against breast 
cancer occurs in women who encounter their FFTB at an early 
age, when circulating IGFI levels are highest. Parous women have 
lower levels of circulating IGFI; therefore, women who undergo 
parity at a young age would forgo exposure to excessive IGFI 
levels (Figure  1). Women who undergo their first pregnancy 
late in life will be exposed to higher circulating IGFI levels until 
after birth (Figure 1). This parallels the breast cancer risk data in 
that women who give birth later are also at higher risk for breast 
cancer.
A link has also been found between IGFI and lobular differ-
entiation. The Nurses Health Studies I and II used 472 women 
with benign breast disease in a cross-sectional design to show 
that higher circulating IGFI or a higher IGF:IGFBP3 ratio was 
associated with decreased odds of having predominantly type 1 
lobules (67). Type 1 lobules are the most undifferentiated lobule 
FiGURe 1 | Circulating iGFi levels parallel breast cancer risk. 
Circulating IGFI levels are lower in parous women compared to nulliparous 
women (black line). A FFTB at an early age (red line) reduces IGFI sooner, 
foregoing the excess circulating IGFI that women who become pregnant for 
the first time later encounter (green line). This parallels the data on breast 
cancer risk, with women who undergo a late FFTB displaying an increased 
breast cancer risk compared to those who undergo an early FFTB.
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type as described previously, or possibly represent involuted lob-
ules as speculated by Baer et al. Findings by Russo et al. show that 
having predominantly type 1 lobules is similar to a nulliparous 
breast architecture and increases risk for breast cancer (26–28), 
but other studies show that having predominately type 1 lobules 
(possibly involuted type 1 lobules) reduces risk for breast cancer 
(30, 31). While conflicting, these data together suggest a role for 
IGFI in lobular breast development and cancer risk. It is possible 
that IGFI contributes breast cancer risk partially by influencing 
differentiation or involution of breast lobules.
The relationship between IGFI and pregnancy is modified 
in women afflicted with gestational diabetes and preeclampsia, 
although the data are conflicting. One study reported an inverse 
association between IGFI or IGFBP1 and risk for gestational dia-
betes (68); another reported a positive association between IGFI 
or IGFBP3 and risk for gestational diabetes (69). While several 
studies show a lack of a correlation between IGFI and/or IGFBP1 
or IGFBP3 and preeclampsia (70–72), the majority report lower 
IGFI in women with preeclampsia (73–75). Other studies found 
that higher IGFI is circulating prior to preeclampsia and in 
gestational hypertension (76, 77). Additionally, data on IGFBPs 
and preeclampsia vary; Ingec and Giudice report higher IGFBP1 
in preeclampsia (70, 73), while Ning and Hietala report lower 
IGFBP1 in preeclampsia (75, 78). Interestingly, a longitudinal 
study looking over the course of pregnancy found that compared 
to healthy controls, during early gestation, IGFBP1 levels were 
lower in women who later developed preeclampsia, but in late 
gestation, BP1 levels were higher than controls (79). This observa-
tion could be converse for IGFI, in that IGFI could first be higher 
prior to the clinical condition of preeclampsia [as suggested above 
(76, 77)] and subsequently reduced with the clinically diagnosed 
preeclampsia (as the majority of the above studies report).
These findings beg the question whether pregnancy disorders 
have associations with breast cancer risk. Again, the data are 
conflicting with many papers finding no association between ges-
tational diabetes or preeclampsia with breast cancer risk (80–84). 
In some reports, glucose intolerance or gestational diabetes was 
associated with an increase in breast cancer risk (85, 86), while 
others found a decrease in risk for breast cancer. One study found 
that patients with gestational diabetes display lower risk for 
premenopausal breast cancer (87). In patients with preeclampsia 
and pregnancy hypertension, a slightly lower breast cancer risk 
was reported (88), and the second study found substantially lower 
breast cancer risk in women with severe preeclampsia if they 
had their first child after the age of 30 (89). Again, the data are 
conflicting, but there could be multiple important considerations 
when assessing breast cancer risk, including timing of pregnancy, 
severity of the disorder during pregnancy, and changes in hor-
mone levels over the course of pregnancy. All of these have yet to 
be directly tested.
In conclusion, long-term exposure to excessive IGFI in cir-
culation leads to an increase in breast cancer risk as described 
above, and parous women display lower circulating IGFI and 
breast cancer risk indicating that IGFI contributes to the effect 
of parity on lifetime breast cancer risk (Figure 2). On the other 
hand, short-term changes in circulating IGFI during complicated 
pregnancies (those experiencing preeclampsia or gestational dia-
betes) may have less of an effect on future risk for breast cancer, 
as studies investigating IGF levels during these complications are 
conflicting as are those investigating breast cancer risk. If women 
who have experienced these complications do in fact have a lower 
risk for breast cancer than healthy parous controls, it may be 
through a mechanism unrelated to IGFI or occurring in a specific 
subset of women.
Rodent Models
Gene expression studies have shown that growth and prolifera-
tion pathways are reduced in parous animals and women. Several 
studies found IGF1 expression to be decreased with parity (48, 
90–92). In a rodent model, circulating GH was reduced in parous 
animals leading to a reduction in mammary gland activation of 
the IGF/GH axis (13, 93). Two rat strains, Sprague Dawley and 
Wister Furth, were bred at 53  days of age and cannulated at 
122 days of age to assess circulating GH. In both strains, aver-
age, as well as peak circulating GH, were significantly reduced 
in parous animals. The reduction in circulating GH translated 
to reduced activation of GH signaling cascades in the mammary 
gland, specifically, phosphorylated Jak2, Stat5A, and Akt (93).
Circulating levels of GH as well as IGFI are obligatory for 
tumor development in certain rodent models. Rats with a genetic 
deletion of GH1 (spontaneous dwarf rats, SDR) are completely 
resistant to carcinogen-induced tumors (94, 95). These animals 
also display reduced circulating IGFI, and IGFI or GH supple-
mentation rescues carcinogen-induced tumorigenesis (96). In the 
SDR model, parity or administering E2 and P4 protects against 
carcinogen-induced GH stimulated tumorigenesis dramatically, 
reducing tumor incidence from 100% (GH alone) to 16.7% 
(GH +  E2 +  P4) and increasing latency from 57 to 138  days, 
respectively (97). IGFI also abolished the protective effect of 
pregnancy. Nulliparous and parous animals were treated with 
IGFI or vehicle for 60  days beginning 7  days prior to carcino-
gen exposure. Parous animals displayed 16% tumor incidence 
compared to AMVs displaying 100% tumor incidence. Further, 
treating parous animals with IGFI resulted in an 83% tumor 
FiGURe 2 | established trends associated with the protective effect of pregnancy. Age at FFTB is positively correlated with breast cancer risk. Women who 
experience an early parity benefit from a long-term protection against breast cancer compared to nulliparous women. Interestingly, higher levels of circulating IGFI 
are also positively associated with breast cancer risk and parous women display lower circulating IGFI levels. Although less firmly established, preeclampsia may be 
associated with a lower breast cancer risk as well as circulating IGFI levels.
5
Katz Pregnancy Age and Breast Cancer Risk
Frontiers in Oncology | www.frontiersin.org October 2016 | Volume 6 | Article 228
incidence, thereby eliminating the protective effect of parity (96). 
IGFI treatment also prevented the induction of lactalbumin in 
the mammary gland, indicating that full differentiation was not 
achieved in these animals. These data support the hypothesis 
that reduced mammary gland differentiation increases tumor 
susceptibility (96).
PReGNANCY RePROGRAMS THe 
ePiGeNOMe, POTeNTiALLY 
CONTRiBUTiNG TO THe PROTeCTive 
eFFeCT AGAiNST BReAST CANCeR
Epigenetic changes play a major role in mammary growth and 
differentiation. DNA is dramatically hypomethylated during 
lactation to open chromatin and allow expression of milk protein 
genes (98). A recent study investigating the effect of parity on 
DNA methylation used MeDIP to pull down methylated regions 
genome-wide and conducted next-generation sequencing in 19 
parous and 16 nulliparous women. They identified FOXA1 to be 
hypermethylated and silenced with parity. Since FOXA1 is known 
to colocalize with ER at enhancers, they believe the silencing of 
FOXA1 will effect ER action, ultimately leading to changes that 
contribute to the protective effect of parity against breast cancer. 
This study also found the IGF acid labile subunit (IGFALS), a 
protein responsible for transport of IGFI in circulation, to be 
hypomethylated with parity. If this hypomethylation leads to a 
change in ALS levels in circulation, this could alter the effects of 
IGFI on target tissues, also contributing to the protective effect 
of parity.
In our recent study, we identified the Igf1r to be hypermeth-
ylated and silenced in parous mammary glands. We harvested 
mammary glands from parous mice and AMVs immediately 
postpartum (early) and 6  months postpartum (late) (99). This 
study design enabled us to identify parity-induced differences 
in DNA methylation, which persist long after pregnancy, 
therefore possibly contributing to the lifelong protective effect 
of pregnancy. We utilized a novel targeted hybridization-based 
approach to identify differentially methylated regions (DMRs). 
Hybridization probes were designed by Agilent to target regions 
of the genome likely to be regulated by DNA methylation, cov-
ering 3.7 million CpG cites in CpG islands, shores, promoters, 
enhancers, introns, exons, and intergenic regions. Our analysis 
identified 624 hypermethylated and 322 hypomethylated genes, 
which were discovered in the early time point and persisted into 
the late time point. The Igf1r was in the top 10 persistently dif-
ferentially methylated genes. The DMR in the Igf1r was located 
in intron 2, the largest intron in the gene. This DMR consisted of 
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five CpG sites, all of which displayed increased DNA methylation 
with parity. Igf1r gene expression was significantly reduced at 
the late time point demonstrating the long-lasting reprogram-
ing effect at this locus. We also looked at other IGF pathway 
members and found several to be significantly hypermethylated 
at the late time point including the ligands Igf1, Igfbp4, Irs1, Prlr, 
and Stat5b. Additionally interesting is that these regions of dif-
ferential DNA methylation also aligned with regions regulated 
by histone modifications as evidenced by in silico analysis in the 
UCSC genome browser. When aligning the DMR in the Igf1r with 
several histone marks, peaks in H3K4me1 and H3K4me3 overlap 
with this portion of intron 2. The same was true for Irs1, Igf1, and 
Igfbp4, each aligning with multiple histone marks. These results 
show that pregnancy induces long-lasting reprograming of the 
epigenome by altering DNA methylation and possibly histone 
modifications. These alterations affect the IGF pathway and may 
contribute to the protective effect of parity.
As previously mentioned, histone modifications are also 
likely to play a role in reprograming the breast epigenome dur-
ing pregnancy. In the breasts of nulliparous women, nuclei were 
large and euchromatic in contrast to parous women displaying 
small heterochromatic nuclei with strong methylation of histones 
at repressive marks H3K9me2 and H3K27me3 (100). One study 
identified H3K27me3 and its writer EZH2 to be increased during 
pregnancy and to decline during late pregnancy, particularly in 
the mammary stem cell population. This regulation was tightly 
correlated with gene expression of pregnancy-associated targets 
such as Csn2 and Wap and was mediated by P4 (101).
CONCLUSiON AND FUTURe DiReCTiONS
Investigations probing the mechanism underlying the protective 
effect of pregnancy against breast cancer have been conducted in 
many areas including lobular differentiation, cell fate, and stromal 
composition. However, no single cause has been identified, and 
likely these mechanisms complexly interact to elicit the protective 
effect. The long-lasting effect of an early FFTB on reducing breast 
cancer risk implies that a relatively persistent modification may 
contribute to this phenomenon such as epigenetic reprograming 
(Figure 3).
While an early FFTB provides the greatest protection against 
breast cancer compared to any other risk factor, a method to 
exploit this phenomenon for a preventative strategy has not been 
developed. Currently, the most widely used preventative measure 
is tamoxifen, but due to toxicities, this is only available to high-
risk women. Tamoxifen therapy causes unpleasant side effects 
leading to a drastic diminishment in its use in more recent years 
(102, 103). There are investigations into IGF1R inhibitors as pre-
ventative therapies, but these are toxic as well and therefore again 
only will be helpful in high-risk women (104–106). With the age 
of FFTB rising and the lack of preventative options, discovering 
the most important mechanisms underlying the protective effect 
of an early FFTB is imperative to developing prevention strategies 
for young healthy women (11, 107). The most effective way to 
eradicate a disease is through prevention; therefore, new preven-
tative avenues for young healthy women are essential to reducing 
breast cancer incidence.
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